DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.
Scholarship aims to support students of color pursuing careers in dentistry to improve access to representative oral care across the state. SEATTLE, June 10,...
NEW YORK, June 10, 2026 /PRNewswire/ -- Attorneys at global law firm Greenberg Traurig, LLP represented Kayne Anderson Real Estate (Kayne Anderson) and BKM...
Sydney, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Australians planning for retirement income face two converging trends. Around 4.4 million Australians are now aged 65 and over, about 17% of the population, with Treasury's Intergenerational Report projecting that share to keep rising through 2063. At the same time, the country's 663,867 self-managed super funds hold A$1.06 trillion in assets across roughly 1.22 million members, according to the latest Australian Taxation Office data. Cash and term deposit allocations across the SMSF sector have fallen to 16.3% of holdings, a record low, as trustees look beyond traditional cash products towards the income side of the portfolio. To learn more visit https://termplus.com.au/how-it-works/
TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- ZOOZ Strategy Ltd. (Nasdaq and TASE: ZOOZ) (“ZOOZ” or the “Company”) today announced that its Board of Directors has authorized management to explore a range of strategic alternatives that could potentially complement the Company’s existing bitcoin treasury strategy and enhance long-term shareholder value.
Detailed Program Agenda Released for 2026 Scientific SessionsBOULDER, Colo., June 10, 2026 /PRNewswire/ -- The American Society for Preventive Cardiology (ASPC) announces its 2026...
NEW YORK, June 10, 2026 /PRNewswire/ -- Following successful validation with leading global retailers and enterprise partners across Europe and the United States, weR...
GREATER SUDBURY, ON, June 10, 2026 /CNW/ - Frontier Lithium Inc. ("Frontier") announces that it has entered into a non-binding memorandum of understanding (the...
As previously announced today in a press release, Ascencio (the “Company”) has launched a capital increase in cash within the limits of the authorised capital via an accelerated bookbuilding process mainly with qualified investors, with a waiver of the preferential subscription rights of existing shareholders.